Logo image
Polygenic Infantile Juvenile Polyposis Syndrome Managed With Sirolimus and Endoscopic Polypectomy
Journal article   Open access

Polygenic Infantile Juvenile Polyposis Syndrome Managed With Sirolimus and Endoscopic Polypectomy

Lisa Dillon Bell, John A. Bernat and Riad Rahhal
Gastroenterology research, Vol.15(1), pp.33-38
01/10/2022
DOI: 10.14740/gr1480
PMCID: PMC8913018
PMID: 35369680
url
https://doi.org/10.14740/gr1480View
Published (Version of record) Open Access

Abstract

In the following clinical case of infantile juvenile polyposis syndrome (JPS), administration of a pharmacologic agent sirolimus was associated with reduced disease burden without need for bowel resection. The positive impact included improvement in protein-losing enteropathy, decreased intestinal blood loss, and improved weight gain. In addition, the number of polyps resected per unit time and frequency of upper and lower endoscopic evaluation needed dropped after initiation of sirolimus. This case report describes a positive clinical outcome and discusses the use of sirolimus with aggressive polypectomy as a potential treatment for the rare disease entity of polygenic infantile JPS. Through this case, we aim to emphasize that while administration of this drug may mitigate many sequelae of infantile JPS, it does not appear to eliminate the need for aggressive polypectomy.
BMPR1A Case Report Hamartoma JPS mTOR PLE PTEN Rapamycin

Details

Logo image